{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:29:28Z","timestamp":1790872168626,"version":"4.1.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1681\/asn.2008121289","type":"journal-article","created":{"date-parts":[[2009,9,3]],"date-time":"2009-09-03T20:59:41Z","timestamp":1252011581000},"page":"2190-2203","source":"Crossref","is-referenced-by-count":101,"title":["Biased Agonist Pharmacochaperones of the AVP V2 Receptor May Treat Congenital Nephrogenic Diabetes Insipidus"],"prefix":"10.1681","volume":"20","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Jean-Alphonse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Perkovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-C\u00e9line","family":"Frantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Durroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"M\u00e9jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Loison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Hibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Mouillac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Mendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20230410","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1043-2760(00)00304-0","article-title":"Vasopressin receptors","volume":"11","author":"Birnbaumer","year":"2000","journal-title":"Trends Endocrinol Metab"},{"key":"R2-17-20230410","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.1091\/mbc.e04-04-0337","article-title":"Regulation of the vasopressin V2 receptor by vasopressin in polarized renal collecting duct cells","volume":"15","author":"Robben","year":"2004","journal-title":"Mol Biol Cell"},{"key":"R3-17-20230410","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/978-1-4615-4871-3_34","article-title":"Molecular pharmacology of human vasopressin receptors","volume":"449","author":"Thibonnier","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"R4-17-20230410","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1146\/annurev.physiol.63.1.607","article-title":"Nephrogenic diabetes insipidus","volume":"63","author":"Morello","year":"2001","journal-title":"Annu Rev Physiol"},{"key":"R5-17-20230410","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1172\/JCI118252","article-title":"Binding-, intracellular transport-, and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus","volume":"96","author":"Tsukaguchi","year":"1995","journal-title":"J Clin Invest"},{"key":"R6-17-20230410","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nature02265","article-title":"Therapeutic approaches to protein-misfolding diseases","volume":"426","author":"Cohen","year":"2003","journal-title":"Nature"},{"key":"R7-17-20230410","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1742-4658.2006.05181.x","article-title":"Protein-misfolding diseases and chaperone-based therapeutic approaches","volume":"273","author":"Chaudhuri","year":"2006","journal-title":"FEBS J"},{"key":"R8-17-20230410","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.coph.2004.08.001","article-title":"Pharmacological chaperone action on G-protein-coupled receptors","volume":"4","author":"Bernier","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"R9-17-20230410","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1600-0854.2004.00232.x","article-title":"Pharmacologic rescue of conformationally-defective proteins: Implications for the treatment of human disease","volume":"5","author":"Ulloa-Aguirre","year":"2004","journal-title":"Traffic"},{"key":"R10-17-20230410","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.tips.2007.06.005","article-title":"The evasive nature of drug efficacy: Implications for drug discovery","volume":"28","author":"Galandrin","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"R11-17-20230410","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1172\/JCI8688","article-title":"Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants","volume":"105","author":"Morello","year":"2000","journal-title":"J Clin Invest"},{"key":"R12-17-20230410","doi-asserted-by":"crossref","first-page":"F253","DOI":"10.1152\/ajprenal.00247.2006","article-title":"Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: Relevance to therapy of nephrogenic diabetes insipidus","volume":"292","author":"Robben","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"R13-17-20230410","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1681\/ASN.2005080854","article-title":"Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus","volume":"17","author":"Bernier","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R14-17-20230410","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1358\/dof.2002.027.03.659890","article-title":"WAY-VNA-932: Vasopressin V2 agonist for treatment of central diabetes insipidus, nocturnal enuresis, nocturia","volume":"27","author":"Caggiano","year":"2002","journal-title":"Drug Future"},{"key":"R15-17-20230410","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1021\/jm000108p","article-title":"Novel design of nonpeptide AVP V(2) receptor agonists: Structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a template","volume":"43","author":"Kondo","year":"2000","journal-title":"J Med Chem"},{"key":"R16-17-20230410","doi-asserted-by":"crossref","first-page":"F265","DOI":"10.1152\/ajprenal.00404.2004","article-title":"Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model","volume":"289","author":"Robben","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"R17-17-20230410","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1210\/mend.16.4.0796","article-title":"Variant amino acids in the extracellular loops of murine and human vasopressin V2 receptors account for differences in cell surface expression and ligand affinity","volume":"16","author":"Oksche","year":"2002","journal-title":"Mol Endocrinol"},{"key":"R18-17-20230410","doi-asserted-by":"crossref","first-page":"47254","DOI":"10.1074\/jbc.M408154200","article-title":"Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors","volume":"279","author":"Wuller","year":"2004","journal-title":"J Biol Chem"},{"key":"R19-17-20230410","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1091\/mbc.e05-06-0579","article-title":"Rescue of vasopressin V2 receptor mutants by chemical chaperones: Specificity and mechanism","volume":"17","author":"Robben","year":"2006","journal-title":"Mol Biol Cell"},{"key":"R20-17-20230410","doi-asserted-by":"crossref","first-page":"35678","DOI":"10.1074\/jbc.M301888200","article-title":"Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation","volume":"278","author":"Tan","year":"2003","journal-title":"J Biol Chem"},{"key":"R21-17-20230410","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1073\/pnas.1936664100","article-title":"Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors","volume":"100","author":"Azzi","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R22-17-20230410","doi-asserted-by":"crossref","first-page":"41541","DOI":"10.1074\/jbc.M306589200","article-title":"Palmitoylation of the V2 vasopressin receptor carboxyl tail enhances beta-arrestin recruitment leading to efficient receptor endocytosis and ERK1\/2 activation","volume":"278","author":"Charest","year":"2003","journal-title":"J Biol Chem"},{"key":"R23-17-20230410","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.cellsig.2006.05.020","article-title":"The V2 vasopressin receptor stimulates ERK1\/2 activity independently of heterotrimeric G protein signaling","volume":"19","author":"Charest","year":"2007","journal-title":"Cell Signal"},{"key":"R24-17-20230410","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1681\/ASN.2005101143","article-title":"Thinking about rare kidney diseases","volume":"17","author":"Shayman","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R25-17-20230410","doi-asserted-by":"crossref","first-page":"20676","DOI":"10.1074\/jbc.M611530200","article-title":"Rescue of a nephrogenic diabetes insipidus-causing vasopressin V2 receptor mutant by cell-penetrating peptides","volume":"282","author":"Oueslati","year":"2007","journal-title":"J Biol Chem"},{"key":"R26-17-20230410","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1242\/jcs.115.14.2907","article-title":"The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation","volume":"115","author":"Saliba","year":"2002","journal-title":"J Cell Sci"},{"key":"R27-17-20230410","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1210\/jcem.87.7.8582","article-title":"Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target","volume":"87","author":"Janovick","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R28-17-20230410","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/emboj\/21.7.1628","article-title":"Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation","volume":"21","author":"Petaja-Repo","year":"2002","journal-title":"EMBO J"},{"key":"R29-17-20230410","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1210\/me.2004-0080","article-title":"Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059","volume":"18","author":"Bernier","year":"2004","journal-title":"Mol Endocrinol"},{"key":"R30-17-20230410","doi-asserted-by":"crossref","first-page":"F257","DOI":"10.1152\/ajprenal.00491.2005","article-title":"Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus","volume":"291","author":"Robben","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"R31-17-20230410","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/sj.embor.7400373","article-title":"Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET","volume":"6","author":"Charest","year":"2005","journal-title":"EMBO Rep"},{"key":"R32-17-20230410","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1073\/pnas.0409534102","article-title":"Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor","volume":"102","author":"Ren","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R33-17-20230410","doi-asserted-by":"crossref","first-page":"14498","DOI":"10.1074\/jbc.M209626200","article-title":"Trafficking patterns of beta-arrestin and G protein-coupled receptors determined by the kinetics of beta-arrestin deubiquitination","volume":"278","author":"Shenoy","year":"2003","journal-title":"J Biol Chem"},{"key":"R34-17-20230410","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1124\/mol.106.028258","article-title":"An opioid agonist that does not induce \u03bc-opioid receptor-arrestin interactions or receptor internalization","volume":"71","author":"Groer","year":"2007","journal-title":"Mol Pharmacol"},{"key":"R35-17-20230410","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1124\/jpet.105.094128","article-title":"Differential efficacies of somatostatin receptor agonists for G-protein activation and desensitization of somatostatin receptor subtype 4-mediated responses","volume":"316","author":"Engstrom","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"R36-17-20230410","doi-asserted-by":"crossref","first-page":"16311","DOI":"10.1074\/jbc.M409945200","article-title":"The oxytocin receptor antagonist atosiban inhibits cell growth via a \u201cbiased agonist\u201d mechanism","volume":"280","author":"Reversi","year":"2005","journal-title":"J Biol Chem"},{"key":"R37-17-20230410","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ab.2004.02.013","article-title":"Cell surface detection of membrane protein interaction with homogeneous time-resolved fluorescence resonance energy transfer technology","volume":"329","author":"Maurel","year":"2004","journal-title":"Anal Biochem"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-200910000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:31:41Z","timestamp":1786131101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-200910000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2008121289","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}